Overview

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temozolomide may also help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. Giving temozolomide together with VNP40101M may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide and VNP40101M in treating patients with relapsed or refractory leukemias.
Phase:
Phase 1
Details
Lead Sponsor:
Vion Pharmaceuticals
Treatments:
Dacarbazine
Temozolomide